In a collaboration with the University of Birmingham, Quark Pharmaceuticals, a Californian based biotech company with research facilities at the Weismann Science Park in Israel, has reported successful results of an anti-apoptotic treatment to halt retinal ganglion cell (RGC) death. RGC death, resulting in vision loss and blindness, has been associated with several ocular pathologies including ischemic optic neuropathy (ION) and glaucoma.